Header Logo

Connection

NAVEEN PEMMARAJU to Morpholines

Back to Details
This is a "connection" page, showing publications NAVEEN PEMMARAJU has written about Morpholines.
NAVEEN PEMMARAJU
Connection Strength
0.129
Morpholines
  1. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11.
    View in: PubMed
    Score: 0.129
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.